Gene-based association identifies SPATA13-AS1 as a pharmacogenomic predictor of inhaled short-acting beta-agonist response in multiple population groups

B. Padhukasahasram*, J. J. Yang, A. M. Levin, M. Yang, E. G. Burchard, R. Kumar, P. Y. Kwok, M. A. Seibold, D. E. Lanfear, L. K. Williams

*Corresponding author for this work

Research output: Contribution to journalArticle

21 Scopus citations

Abstract

Inhaled short-acting beta-agonist (SABA) medication is commonly used in asthma patients to rapidly reverse airway obstruction and improve acute symptoms. We performed a genome-wide association study of SABA medication response using gene-based association tests. A linear mixed model approach was first used for single-nucleotide polymorphism associations, and the results were later combined using GATES to generate gene-based associations. Our results identified SPATA13-AS1 as being significantly associated with SABA bronchodilator response in 328 healthy African Americans. In replication, this gene was associated with SABA response among the two separate groups of African Americans with asthma (n=1073, P=0.011 and n=1968, P=0.014), 149 healthy African Americans (P=0.003) and 556 European Americans with asthma (P=0.041). SPATA13-AS1 was also associated with longitudinal SABA medication usage in the two separate groups of African Americans with asthma (n=658, P=0.047 and n=1968, P=0.025). Future studies are needed to delineate the precise mechanism by which SPATA13-AS1 may influence SABA response.

Original languageEnglish (US)
Pages (from-to)365-371
Number of pages7
JournalPharmacogenomics Journal
Volume14
Issue number4
DOIs
StatePublished - Aug 2014

Keywords

  • adrenergic beta agonists
  • asthma
  • bronchodilator agents
  • genome-wide association study
  • lung function tests
  • pharmacogenomics

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology

Fingerprint Dive into the research topics of 'Gene-based association identifies SPATA13-AS1 as a pharmacogenomic predictor of inhaled short-acting beta-agonist response in multiple population groups'. Together they form a unique fingerprint.

  • Cite this

    Padhukasahasram, B., Yang, J. J., Levin, A. M., Yang, M., Burchard, E. G., Kumar, R., Kwok, P. Y., Seibold, M. A., Lanfear, D. E., & Williams, L. K. (2014). Gene-based association identifies SPATA13-AS1 as a pharmacogenomic predictor of inhaled short-acting beta-agonist response in multiple population groups. Pharmacogenomics Journal, 14(4), 365-371. https://doi.org/10.1038/tpj.2013.49